Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=tb-500,thymosin-beta-4

Side-by-side comparison of TB-500, Thymosin beta-4
TB-500Thymosin beta-4
Identity
ClassSynthetic acetylated heptapeptide corresponding to the actin-binding region of thymosin beta-4 (residues 17–23)43-residue N-terminally acetylated peptide; the parent molecule of the TB-500 fragment
Also listed asThymosin beta-4 fragment (LKKTETQ), Ac-LKKTETQ-OH, TB500Timbetasin, Thymosin β4, Tβ4
Molecular formulaC38H68N10O14C212H350N56O78S
Molecular weight889.0 g/mol4963 g/mol
CAS885340-08-977591-33-4
PubChem CID6270766216132341
Sequence length7 residues43 residues
Data caveatTB-500 is commonly described in vendor material as the Ac-SDKP fragment. Full caveatMuch of the wound-healing literature cited in commercial TB-500 material concerns this full-length peptide. Full caveat
United States regulatory status
StatusNo FDA-approved productNo FDA-approved product
FDA applicationNone recordedNone recorded
CompoundingFDA bulk-substance nomination withdrawn; safety concerns remain published.No FDA compounding entry recorded
WADANamed at S2.3 — “Thymosin-β4 and its derivatives e.g. TB-500”. Prohibited at all times; non-Specified.Named at S2.3 — “Thymosin-β4 and its derivatives e.g. TB-500”, among growth factors and growth factor modulators. Prohibited at all times.
Research profile
Research purposePreclinical actin-binding fragment researchNo plain-English profile recorded
Proposed mechanismCorresponds to the actin-binding region of thymosin beta-4. The proposed mechanism is actin cytoskeletal regulation and cell migration; direct human evidence for the fragment is very limited.No plain-English profile recorded
Human evidenceMost wound-healing human data concern full-length thymosin beta-4, a different molecule. Therapept indexes no human interventional trial of the TB-500 fragment itself.No plain-English profile recorded
Evidence tierPreclinical models; no human efficacy trial indexedNo plain-English profile recorded
Known safety concerns
  • No approved product; FDA published aggregation and immunogenicity concerns and stated it had not identified human exposure data for the fragment.
  • Named on the WADA Prohibited List at S2.3 as a thymosin-beta-4 derivative.
  • Human safety of the fragment is essentially uncharacterised.
No plain-English profile recorded
Evidence gaps
  • Any human interventional data for the fragment.
  • Whether the actin-binding fragment reproduces the parent protein's effects.
  • Long-term safety.
No plain-English profile recorded
Head-to-head evidenceNo published head-to-head trial against BPC-157 or full-length thymosin beta-4.No plain-English profile recorded
Named pathwaysActin cytoskeleton · Cell migration · Thymosin beta-4 biologyNo plain-English profile recorded
Evidence on file
Records
Human-interventional records00
Human-observational records00
Animal records10
In-vitro records00
Reviews20
Regulatory documents30
Earliest indexed1999Not recorded
Latest indexed2026Not recorded

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.